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Abstract
Background: Plasmodium vivax Duffy binding protein (PvDBP) plays an essential role in erythrocyte invasion and a
potential asexual blood stage vaccine candidate antigen against P. vivax. The polymorphic nature of PvDBP,
particularly amino terminal cysteine-rich region (PvDBPII), represents a major impediment to the successful design
of a protective vaccine against vivax malaria. In this study, the genetic polymorphism and natural selection at
PvDBPII among Myanmar P. vivax isolates were analysed.
Methods: Fifty-four P. vivax infected blood samples collected from patients in Myanmar were used. The region
flanking PvDBPII was amplified by PCR, cloned into Escherichia coli, and sequenced. The polymorphic characters
and natural selection of the region were analysed using the DnaSP and MEGA4 programs.
Results: Thirty-two point mutations (28 non-synonymous and four synonymous mutations) were identified in
PvDBPII among the Myanmar P. vivax isolates. Sequence analyses revealed that 12 different PvDBPII haplotypes
were identified in Myanmar P. vivax isolates and that the region has evolved under positive natural selection. High
selective pressure preferentially acted on regions identified as B- and T-cell epitopes of PvDBPII. Recombination
may also be played a role in the resulting genetic diversity of PvDBPII.
Conclusions: PvDBPII of Myanmar P. vivax isolates displays a high level of genetic polymorphism and is under
selective pressure. Myanmar P. vivax isolates share distinct types of PvDBPII alleles that are different from those of
other geographical areas. These results will be useful for understanding the nature of the P. vivax population in
Myanmar and for development of PvDBPII-based vaccine.
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Background
Plasmodium vivax Duffy binding protein (PvDBP) is one
of the erythrocyte-binding proteins, which belongs to
the large erythrocyte binding protein family [1]. PvDBP
is expressed on the merozoite of P. vivax and plays an
essential role in erythrocyte invasion of the parasite by
mediating irreversible binding with its corresponding
receptor, the duffy antigen receptor for chemokines
(DARC), on the surface of erythrocytes [1-4]. Similar to
other plasmodial proteins known to participate in such
processes, PvDBP is suggested to be an important vac-
cine candidate antigen, because it elicits strong immune
responses in humans [5,6]. Experimental evidences that
antibodies against PvDBP inhibit the interaction of this
protein with DARC in vitro and block the invasion of
P. vivax into human erythrocytes also support the
notion that this protein is a potential asexual blood
stage vaccine candidate antigen against P. vivax [7-9].
PvDBP is divided into seven regions (regions I-VII),
and the amino terminal cysteine-rich region, region II
(PvDBPII), contains the central binding motifs necessary
for adherence to DARC [10-12]. Critical binding motifs
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stretch (amino acids 291-460), which includes cysteines
5-8 [11,12]. PvDBPII shows the highest genetic diversity
compared to the remaining PvDBP regions and appears
to be under strong selective pressure [13,14]. Analysis of
genetic variation of PvDBPII among P. vivax field isolates
from different geographical regions, including Brazil,
Colombia, South Korea, Papua New Guinea, Thailand,
showed that the PvDBPII is highly polymorphic, but the
cysteine residues are conserved within and between
P. vivax populations from different geographic regions
[14-21]. Although it has been suggested that these poly-
morphisms do not significantly alter host-parasite bind-
ing [17,22], some of them alter immune recognition of
PvDBP [23] and most of the PvDBP-specific antibodies
detected in infected individuals recognize PvDBPII,
rather than other PvDBP regions [7,15]. Consequently,
the polymorphic nature of PvDBP, particularly PvDBPII,
represents a major impediment to the successful design
of a protective vaccine against vivax malaria [14]. There-
fore, understanding the nature and genetic polymorph-
ism in PvDBPII among P. vivax isolates from distinct
geographic areas, particularly where a large proportion of
P. vivax infections occurs, is important for the rational
design of vaccines against vivax malaria.
In this study, the genetic polymorphism and natural
selection of PvDBPII among P. vivax isolates from Myan-
mar were analysed. These results suggest that excessive
polymorphism of PvDBPII is found in the filed isolates of
P. vivax in Myanmar.
Methods
Blood samples and DNA preparation
The 54 blood samples used in this study were collected
from patients who were infected with Plasmodium vivax
at Wet-Won Station Hospital, Pyin Oo Lwin township,
Mandalay Division, Myanmar between 2004 and 2006
[24]. The confirmation of P. vivax infection was performed
by microscopic examination of thin and thick blood
smears and polymerase chain reaction [24]. Informed con-
sent was obtained from all individuals participating in this
study before blood sampling under the protocol approved
by the Department of Health, The Union of Myanmar,
and the Ethics Committee of the Centers for Disease Con-
trol and Prevention, Korea. Genomic DNA was extracted
from 200 μl of whole blood using a QIAamp Blood kit
(Qiagen, Valencia, CA, USA), according to the manufac-
turer’si n s t r u c t i o n .
Amplification and sequencing analysis of PvDBPII
Amplification of the PvDBPII region was performed by
the polymerase chain reaction (PCR) using the specific
primers, PvDBPII F: 5’-ACCACGATCTCTAGTGC-
TATTATA-3’ and PvDBPII R: 5’-ATTTGTCACAACTT
CCTGAGTATT-3’. The amplification reaction was per-
formed using the following thermal cycling profile: 94°C
for 5 min, 30 cycles at 94°C for 1 min, 50°C for 1 min,
and 72°C for 1 min, followed by a 72°C extension for 10
min. Ex Taq DNA polymerase (Takara, Otsu, Japan) was
used in all PCR reactions to prevent any possible nucleo-
tide mis-incorporation. The PCR product was analysed on
a 1.2% agarose gel, gel-purified, and ligated into the T&A
cloning vector (Real Biotech Cooperation, Banqiaa City,
Taiwan). Each ligation mixture was transformed into
Escherichia coli DH5a competent cells, and positive clones
were screened for the presence of the plasmid with the
appropriate insert. The sequencing reaction was per-
formed using the BigDye Terminator Cycle Sequencing
Ready Reaction kit in an ABI 377 automatic DNA sequen-
cer (Applied Biosystems, Foster City, CA, USA). To verify
the sequences, sequence analysis was performed by analys-
ing at least two clones from each isolate.
Sequence and phylogenetic analyses
Nucleotide and deduced amino acid sequences were ana-
lysed using the EditSeq program and Clustal in the
Megalign program, a multiple alignment program of the
D N A S T A Rp a c k a g e( D N A S T A R ,M a d i s o n ,W I ,U S A ) .
The phylogeny tree was constructed using the neighbour-
joining method with MEGA4 version 4.0 [25]. Bootstrap
proportions were used to assess the robustness of the tree
with 1,000 bootstrap replications. The sequences reported
here have been deposited in the GenBank database under
the accession numbers JN255576-JN255587.
DNA sequence polymorphism analysis
DNA sequence polymorphism analysis was performed on
54 Myanmar PvDBPII sequences. The number of segregat-
ing sites (S), haplotype diversity (Hd), nucleotide diversity
(π), and average number of pairwise nucleotide differences
within the population (K) were calculated using the
DnaSP ver. 5.10.00 package [26]. The π was also calculated
on a sliding window of 100 bases, with a step size of 25 bp
to estimate the stepwise diversity across PvDBPII. The
rates of synonymous (Ks) and non-synonymous (Kn) sub-
stitutions were estimated and compared by the Z-test (P <
0.05) in MEGA4 program [25] using the Nei and Gojo-
bori’s method [27] with the Jukes and Cantor correction.
Tajima’sDt e s t[ 2 8 ]a n dF ua n dL i ’s D and F tests using
P. knowlesi PvDBPII as an outgroup [29] were performed
on DnaSP 5.10.00 to test the neutral theory of evolution.
Analysis of polymorphism associated with B- and T- cell
epitopes
To assess the possibility that diversity in PvDBPII within
the Myanmar P. vivax isolates may have arisen from
host’s immune pressure, the genetic diversity in predicted
or known B- and T-cell epitopes [14] and MHC binding
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each region was analysed by DnaSP ver. 5.10.00 [26], as
described above.
Recombination parameters and linkage disequilibrium
The recombination parameter (R), which included the
effective population size and probability of recombination
between adjacent nucleotides per generation, and the
minimum number of recombination events (Rm) were
measured using DnaSP ver. 5.10.00 [26]. Linkage disequili-
brium (LD) between different polymorphic sites was com-
puted in terms of the R
2 index.
Results
Genetic polymorphisms and amino acid changes
The region corresponding to PvDBPII was amplified from
the 54 Myanmar P. vivax isolates by PCR. Each amplified
product was cloned into the T&A cloning vector and
sequenced in both directions. To verify the sequences,
sequencing reactions were performed for at least two plas-
mid clones for each gene. No size polymorphism was
found between the sequences. Analysis and comparison of
the sequences against the Sal I (DQ156512) as a reference
sequence at the nucleotide level showed that point muta-
tions occurred at 32 positions among the Myanmar iso-
lates. Twelve of these 32 mutations occurred at the first
base of the codon, 10 at the second base and 10 at the
third base of the codon, resulting in significant amino acid
changes (28 non-synonymous and four synonymous muta-
tions) across the PvDBPII among Myanmar isolates. Most
of the non-synonymous polymorphisms were non-conser-
vative, resulting in changes in the physico-chemical family
of the respective amino acid. A sequence analysis of the
deduced amino acid sequences classified them into 12 dif-
ferent haplotypes (haplotypes 1-12) with amino acid
changes at 28 positions, in which 1 showed a trimorphic
polymorphism (position 386) and the others were
dimorphic (Figure 1A). Seventeen of the 28 changes were
previously reported, whereas the remaining 11 changes
(I310L, F344S, R391H, K455I, K473R, C477G, R490K,
D528G, V533M, K541T, and A545V) were new changes
that have not been reported previously. Haplotype 3 was
predominant (n = 16, 29.6%) among the Myanmar isolates.
High frequencies of variant amino acids (> 50%), com-
pared to the Sal I sequence, were found for L333F (27/54,
50.0%), D384G (46/54, 85.2%), R390H (34/54, 63.0%),
L424I (45/54, 83.3%), W437R (33/54, 61.1%), and I503K
(42/54, 77.7%) (Figure 1B). A BLAST search was con-
ducted in the GenBank database to compare these haplo-
types with the previously identified PvDBPII sequences.
Comparison of the 12 haplotypes found in the Myanmar
P. vivax isolates with the GenBank sequences revealed
that 10 of them (except haplotypes 1 and 8) were novel.
Phylogenetic analysis revealed that the 12 Myanmar
haplotypes were widely distributed among different iso-
lates from distinct geographic regions (Figure 2). Compari-
s o no ft h em o s tc o m m o nv a r i a n t si nP v D B P I Ia m o n g
presently studied P. vivax populations revealed that Myan-
mar isolates showed a pattern similar to Thailand isolates
[20] but one that differed from Papua New Guinean,
Colombian, Brazilian, Iranian, and Sri Lankan isolates
[19,21,31] (Table 1). Although the Myanmar isolates
showed similar amino acid changes compared to Thailand
isolates, nine variants found in the Thailand isolates
(R268S, S351C, I367T, S398T, T404R, Q433K, R436T,
N507H, and T513K) were not identified in the Myanmar
isolates. Meanwhile, 11 variations (I310L, F343S, R391H,
K455I, K473R, C477G, R490K, D528G, V533M, K541T,
and A545V) found in the Myanmar isolates did not occur
in the Thailand isolates.
Nucleotide diversity and natural selection of PvDBPII
DNA sequence analyses were conducted to determine
nucleotide diversity and genetic differentiation at
PvDBPII among the Myanmar P. vivax isolates. The
average number of pairwise nucleotide differences (K)
for the 963 bp of the PvDBPII region was 7.851 (Table
2). The overall haplotype diversity (Hd) and nucleotide
diversity (π) for all 54 sequences were 0.875 ± 0.029 and
0.0079 ± 0.0004, respectively (Table 2). Further analysis,
with a sliding window plot (window length 100 bp, step
size 25 bp) using the DnaSP package, revealed that π
diversity ranged from 0 to 0.027. The two highest peaks
of nucleotide diversity within the PvDBPII region were
identified between nucleotide positions 370-580 (Figure
3A). To determine whether natural selection contributed
to generation of this diversity in PvDBPII within the
Myanmar P. vivax population, the rate of non-synon-
ymous (Kn) to synonymous substitutions (Ks) was esti-
mated using the Nei and Gojobori’s method [27], as
implemented in the MEGA4 program [25]. The stan-
dard error was determined by 1,000 bootstrap replica-
t i o n s .T h er a t eo fn o n - s y n o n y m o u ss u b s t i t u t i o n s( Kn)
(0.00917) exceeded the rate of synonymous substitutions
(Ks) (0.00278). The Kn/Ks ratio was 3.299 (Table 2).
These results suggest that positive natural selection may
be occurring in PvDBPII and favoring fixed amino acid
replacement in certain areas of the protein. The Taji-
ma’s D statistics was 0.264 (P > 0.1), indicating a
decrease in population size and/or balancing selection.
The Fu and Li’s D and F values were 1.867 (P < 0.02)
and 1.535 (0.1 > P > 0.05), respectively.
Polymorphisms associated with B- and T-cell epitopes
To evaluate the association between positive natural selec-
tion and host immune evasion, we examined the genetic
diversity in predicted or known B- and T-cell epitopes
[14] and MHC binding regions [30] in PvDBPII. Most
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regions were polymorphic, and most had a higher rate of
non-synonymous mutations (Kn) than that of synonymous
mutations (Ks) with the exceptions being the regions
within peptides 13 and Ic (Table 3). High levels of nucleo-
tide diversity were particularly found in peptides 48 and
Ia, which contained spatially proximate polymorphic resi-
dues at positions 417, 419, and 427 and positions 385, 386,
390, and 391, respectively, and they showed a clear posi-
tive natural selection signature with positive Tajima’sD
values. In contrast, three peptides (28, 40 and 54), which
did not contain known epitopes [14], had lower nucleotide
diversity. These results are consistent with the hypothesis
that natural selection acts on epitopes in PvDBPII and is
related to diversity of PvDBPII [14,30].
Recombination
The minimum number of recombination events between
adjacent polymorphic sites (Rm) was 7, whereas R between
adjacent sites (Ra) and per gene (Rb) was 0.0314 and 30.2,
respectively. The high value of the recombination para-
meters indicated that high meiotic recombination may
occur between sites, resulting in genetic diversity in the
PvDBPII. The LD index R
2 for the Myanmar population
also declined across the analysed region, suggesting that
intragenic recombination may also be contributing the
increased diversity at PvDBPII (Figure 3B).
Discussion
Malaria is endemic or hypoendemic in Myanmar and is
characterized by the occurrence of all four human-
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and mortality rates due to malaria have been declining
gradually in recent years, Myanmar still contributes to
approximately 60% of malaria deaths in the Southeast
Asia [32]. Genetic polymorphisms in the circumsporo-
zoite protein, merozoite surface protein-1 (MSP-1),
MSP-3a, and apical membrane antigen-1 (AMA-1) of
P. vivax Myanmar isolates were analysed previously
[24,33,34]. As expected, they showed high levels of
genetic polymorphisms, but information on the nature
and extent of population diversity within malaria para-
sites in Myanmar is still limited. In this study, genetic
polymorphism and natural selection of PvDBPII in
Myanmar P. vivax isolates were analysed to expand our
knowledge on population diversity of the parasite in the
country.
A total of 54 PvDBPII sequences were obtained from
Myanmar P. vivax isolates. The sequence analysis revealed
that the 54 sequences were classified into 12 different hap-
lotypes. A GenBank search for each haplotype revealed
that two haplotypes were identical to at least one pre-
viously reported PvDBPII sequence found in other regions
of the world, whereas the other 10 haplotypes were novel
and have not been reported so far. The sequence analysis
revealed that a total of 32 point mutations was identified,
which resulted in significant amino acid changes (28 non-
synonymous and four synonymous changes) through the
PvDBPII in Myanmar isolates. Seventeen of the 28 non-
synonymous changes were previously reported, whereas
the other 11 changes (I310L, F344S, R391H, K455I,
K473R, C477G, R490K, D528G, V533M, K541T, and
A545V) were unique to Myanmar isolates, which did not
hitherto identified. The two highest peaks of nucleotide
diversity within PvDBPII in the Myanmar P. vivax isolates
were identified between C5 and C7, which was consistent
with previous observations [14,15,17]. Interestingly, a
unique amino acid change (C477G caused by TGT to
GGT) was identified in three Myanmar isolates. It is well
known that the cysteine residues within PvDBPII are well
conserved within and between P. vivax populations from
different geographic regions studies [14-21,31]. It is not
certain the nature of this amino acid change. It can be
assumed that this mutation may resulted from a PCR or
sequencing error, but to eliminate any possible errors,
high quality Taq polymerase with a proof-reading function
was used in all amplification processes and sequencing
reactions were performed on at least two individual clones
for each gene in both directions. But, considering the
small number of isolates used in this study, further ana-
lyses with a large number of isolates is necessary to con-
firm this change in the Myanmar P. vivax isolates. Taken
together, the results of this study suggest that PvDBPII in
the Myanmar isolates showed a high level of genetic poly-
morphism with a nucleotide diversity (π) of 0.0079 ±
0.0004.
Some polymorphic residues in PvDBPII occurred in only
one population or geographic region, but common variant
amino acids (K371E, D384G, E385K, K386N, N417K,
L424I, W437R and I503K) are found in global isolates
[19-21,31]. A high frequency (> 50%) of D384G (85.2%),
R390H (63.0%), L424I (83.3%), W437R (61.1%), and I503K
(77.7%) residues were found in Myanmar isolates com-
pared to that in the Sal I sequence. This was highly similar
to a report on Thailand isolates (D384G, 76.7%; R390H,
Table 1 Frequencies of the most common variant amino acids in PvDBPII
F306L R308S D384G K386N K386Q N417K L424I W437R S447K I503K
Myanmar 7.4 22.2 85.2 33.3 5.6 38.9 83.3 61.1 0 77.8
Thailand
a 6.7 26.7 76.7 40.0 3.0 36.6 86.7 63.3 0 56.7
Iran
b 5.3 6.6 61.3 6.6 0 44.0 50.6 45.3 0 70.6
Sri Lanka
c 7.0 13.0 94.0 20.0 0 36.0 49.0 37.0 0 55.0
Papua New Guinea
d 0 67.0 66.0 8.0 11.0 23.0 34.0 26.0 59.0 29.0
Colombia
d 0 0 59.0 23.0 0 47.0 47.0 18.0 0 12.0
Brazil
d 0 12.5 85.0 12.5 0 27.5 32.5 27.5 0 55.0
a [20];
b [21];
c [31];
d [19]
The first letter represents the amino acid in that position in Sal I sequence, and the other letter represents the substituted amino acid
Table 2 Estimates of DNA sequence polymorphism and tests of neutrality at PvDBPII among Myanmar isolates
Total
no.
of
isolates
Segregating
sites (S)
Singleton
variable sites
Parsimony
informative sites
Total no.
of
mutations
K HH d ± S D π ±S D Kn Ks Tajima’s
54 32 0 32 32 7.581 12 0.875 ±
0.029
0.0079 ±
0.0004
0.00917 0.00278 0.264 (P >
0.1)
K, average number of pairwise nucleotide differences; H, number of haplotypes; Hd, haplotype diversity; π, observed average pairwise nucleotid diversity; Kn, rate
of non-synonymous mutations; Ks, rate of synonymous mutations
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Page 6 of 1156.7%; L424I, 86.7%; W437R, 63.3%; I503K, 56.7%) [20]
but differed from previous studies showing R308S (67%),
D384G (66%), and S447K (59%) in Papua New Guinean
isolates; D384G (59%) in Colombian isolates; D384G
(85%) and I503K (55%) in Brazilian isolates; D384G
(61.3%) and I503K (70.6%) in Iranian isolates; and D384G
(94%) and I503K (55%) in Sri Lankan isolates [19,21,31].
F306L, which has only been reported from Asian malaria
Nucleotide Position
˭ ˭ ˭ ˭
A
R2
B
Nucleotide Position
Figure 3 Natural selection of PvDBPII. (A) Sliding window plot of nucleotide diversity per site (π) comparing the level of genetic diversity at
PvDBPII. The π values were calculated on DnaSP with window length 100 bp and step size of 25 bp. (B) The linkage disequilibrium (LD) plot
showing non-random association between nucleotide variants in 54 Myanmar P. vivax isolates at different polymorphic sites. The R
2 values are
plotted against the nucleotide distances with two-tailed Fisher’s exact test of significance.
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Page 7 of 11Table 3 Polymorphism observed in the each epitope sequence
Epitope name Epitop
a Segregating sites (S) Singleto
n variable
sites
Parsimony
informative sites
Total no.
of mutations
K HH d ± S D π ±S D Kn Ks Tajima’sD
5 T/B 3 0 3 3 0.565 4 0.383 ± 0.079 0.013 ± 0.003 0.016 0 -0.289 (P > 0.1)
13 T 0 0 0 0 0 1 0 0 0 0 0
16 T/B 1 0 1 1 0.509 2 0.509 ± 0.013 0.011 ± 0.000 0.015 0 1.741 (P > 0.05)
18 B 1 0 1 1 0.509 2 0.509 ± 0.013 0.011 ± 0.000 0.015 0 1.741 (P > 0.05)
20 T/B 1 0 1 1 0.509 2 0.509 ± 0.013 0.011 ± 0.000 0.014 0 1.741 (P > 0.05)
28 None 0 0 0 0 0 1 0 0 0 0 0
40 None 3 0 3 3 0.867 3 0.542 ± 0.059 0.019 ± 0.003 0.018 0.025 0.642 (P > 0.1)
48 B 5 0 5 5 1.560 6 0.748 ± 0.040 0.035 ± 0.003 0.041 0 1.007 (P > 0.1)
54 None 0 0 0 0 0 1 0 0 0 0 0
66 T 1 0 1 1 0.283 2 0.283 ± 0.068 0.006 ± 0.002 0.008 0 0.382 (P > 0.1)
78 B 1 0 1 1 0.107 2 0.107 ± 0.055 0.002 ± 0.001 0.003 0 -0.675 (P > 0.1)
Ia MHCIa 3 0 3 3 0.907 4 0.649 ± 0.037 0.034 ± 0.004 0.040 0 0.767 (P > 0.1)
Ib MHCIb 2 0 2 2 0.214 2 0.107 ± 0.055 0.008 ± 0.004 0.010 0 -0.898 (P > 0.1)
Ic MHCIc 2 0 2 2 0.492 3 0.458 ± 0.066 0.012 ± 0.002 0.011 0.017 0.212 (P > 0.1)
IIa MHCIIa 2 0 2 2 0.557 3 0.511 ± 0.043 0.019 ± 0.002 0.021 0.011 0.471 (P > 0.1)
IIb MHCIIb 2 0 2 2 0.423 3 0.297 ± 0.076 0.016 ± 0.004 0.019 0 -0.064 (P > 0.1)
K, average number of pairwise nucleotide differences; H, number of haplotypes; Hd, haplotype diversity; π, observed average pairwise nucleotide diversity; Kn, rate of non-synonymous mutations; Ks, rate of
synonymous mutations.
aB, B-cell epitope; T, T-cell epitope; none, no epitope identified
J
u
e
t
a
l
.
M
a
l
a
r
i
a
J
o
u
r
n
a
l
2
0
1
2
,
1
1
:
6
0
h
t
t
p
:
/
/
w
w
w
.
m
a
l
a
r
i
a
j
o
u
r
n
a
l
.
c
o
m
/
c
o
n
t
e
n
t
/
1
1
/
1
/
6
0
P
a
g
e
8
o
f
1
1endemic areas, including Thailand [20], Iran [21], and Sri
Lanka [31], was also identified in the Myanmar isolates.
Although the Myanmar isolates showed similar amino
acid changes compared to those in the Thailand isolates, 9
variants found in the Thailand isolates (R268S, S351C,
I367T, S398T, T404R, Q433K, R436T, N507H, and
T513K) were not identified in the Myanmar isolates.
Meanwhile, 11 variations (I310L, F344S, R391H, K455I,
K473R, C477G, R490K, D528G, V533M, K541T, and
A545V) found in the Myanmar isolates did not occur in
the Thailand isolates. These results indicate that the Myan-
mar isolates are different from the Thailand isolates even
though the two countries are very close geographically.
Although polymorphic residues were widely distributed
throughout the PvDBPII sequence, polymorphisms at resi-
dues 417, 437, and 503, either in single or in combination,
can affect the efficacy of inhibitory antibodies against ery-
throcyte binding [23,35]. As these residues compose an
important discontinuous epitope in PvDBP, which might
be the main target for inhibitory antibodies, these poly-
morphisms could be subject to immune pressure responsi-
ble for parasite escape from the host immune system. It
has been confirmed that this strong positive selection
pressure in PvDBPII promotes greater diversity [14,30].
The immune pressure drives the generation of new
PvDBP variants that are still able to bind erythrocytes but
become resistant to inhibitory antibodies, suggesting that
this DBP region is under positive pressure at critical resi-
dues and under negative pressure at the residues involved
in receptor recognition [22,23,35]. A low prevalence of
variant N417K (38.9%) was observed among Myanmar iso-
lates, but more than 50% of W437R (61.1%) and I503K
(77.8%) were identified. Analyses of the combination of
variants revealed that W437R-I503K occurred at a higher
frequency (70.4%), whereas N417K-W437K and N417K-
I503K occurred at frequencies of 38.9% and 25.9%, respec-
tively. This result suggests that there is a strong associa-
tion between W437R-I503K in PvDBPII in Myanmar
P. vivax isolates, but not between N417K with either
W437R or I503K.
The rate of non-synonymous mutations (Kn) and that of
synonymous mutations (Ks) is generally used as an indica-
tor of the action of natural selection in most coding gene
sequences [27]. Negative selection acting on coding genes
can usually be identified when non-synonymous mutations
are not advantageous, so the rate of synonymous muta-
tions surpasses that of non-synonymous mutations (Ks
>Kn). Meanwhile, positive selection is acting on a gene,
when non-synonymous mutations can be beneficial (e.g.
to avoid the host immune response), and the rate of non-
synonymous mutations exceed that of synonymous muta-
tions (Kn >K s). Previous studies on PvDBPII diversity
indicate that the high rate of non-synonymous mutations
(Kn) relative to that of synonymous mutations (Ks) reflects
positive selection pressure [14,31,36]. The positive value of
Kn/Ks (3.299) for all 54 sequences suggest that PvDBPII in
Myanmar P. vivax isolates is under positive natural selec-
tion. The positive values of Tajima’s D (0.2635, P > 0.10)
and Fu and Li’s D (1.867, P < 0.02) and F statistics (1.535,
0.1 > P > 0.05) indicate that PvDBPII alleles occur at more
intermediate frequencies than expected and that few
alleles are rare or near fixation, which is consistent with
the action of balancing selection, which maintains allelic
variation in a population. These results collectively sug-
gested that strong balancing selection, probably by host
immune selection pressure, occurs at PvDBPII in the
Myanmar isolates.
Polymorphism in B- and T-cell epitopes of parasite anti-
gens may well enable parasites to escape host immune
responses, as a polymorphism in the epitopes can up or
down regulate T-cell responses to the index peptide or
completely arrest an immune response, assisting escape of
the parasite from the host immune system [37]. The high
degree of nucleotide diversity and high rates of non-
synonymous to synonymous mutations are observed in
known or predicted B- and T-cell epitopes and MHC
binding regions of PvDBPII in the Myanmar isolates.
Overall nucleotide diversity values for these epitopes and
regions were greater than those for the entire PvDBPII. In
particular, high levels of nucleotide diversity were identi-
fied in peptides 48 and Ia, which is comparable to Brazi-
lian isolates [30]. Positive Tajima’sDv a l u e sf o rt h e s e
epitopes also suggested that positive natural selection pre-
ferentially acted on the epitopes in PvDBPII in the Myan-
mar isolates. These epitopes are predicted to be exposed
to the surface of the PvDBP molecule [30]. The putative
changes in protein structure may alter antibody binding
efficacy of a particular epitope, thereby allowing escape
from the host protective immune response [13,30].
Many factors may contribute to genetic diversity in
malaria populations, including mutations, intragenic
recombination, natural selection, gene flow between differ-
ent regions, and population size. Although it remains con-
troversial, it has been suggested that recombination also
contributes to the diversity of PvDBPII [30,36]. The exis-
tence of recombination events and the decline in the LD
with increasing distance between nucleotide sites suggest
that in addition to natural selection meiotic recombination
may also contribute to maintain the diversity of PvDBPII
among Myanmar P. vivax isolates, as reported previously
in Brazil, Colombia, and Sri Lanka [30,31].
Conclusion
The present study is the first report on the genetic poly-
morphism and natural selection of PvDBPII in Myanmar
P. vivax isolates. Myanmar P. vivax isolates are genetically
diverse and this seems to have arisen by a immune evasion
mechanism, in which positive natural selection and
Ju et al. Malaria Journal 2012, 11:60
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Page 9 of 11recombination events maintained the diversity in the form
of balancing selection. However, further studies using a
larger number of isolates collected from different geogra-
phical regions in Myanmar will be helpful to reveal the
nationwide parasite heterogeneity and the implementation
of malarial control programmes in Myanmar.
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